Literature DB >> 12170266

Magnitude of IFN-gamma production in HIV-1-infected children is associated with virus suppression.

James M Reuben1, Bang-Ning Lee, Mary Paul, Mark W Kline, Stanley G Cron, Stuart Abramson, Dorothy Lewis, Claudia A Kozinetz, William T Shearer.   

Abstract

BACKGROUND: Little is known about the cytokine production by peripheral blood cells of pediatric patients who have suppressed HIV-1 replication after highly active antiretroviral therapy (HAART).
OBJECTIVE: We sought to determine the effect of HAART on the production of T(H)1 and T(H)2 cytokines by HIV-infected children who have suppressed HIV replication.
METHODS: At 3- to 6-month intervals over a 5-year period, CD4(+) T cells were enumerated, plasma HIV-1 RNA was measured, and levels of cytokine production by whole blood cultures were determined in 21 HIV-1-infected children.
RESULTS: Ten patients achieved an HIV-1 RNA level of less than 3000 copies/mL of plasma and maintained that level for at least 15 months (virus-suppressed [VS] group). Eleven patients had a mean HIV-1 RNA level of greater than 10(4) copies/mL of plasma and a mean CD4(+) T-cell count of less than 500/microL of blood (active infection group). The median levels of anti-CD3-induced IL-2, IFN-gamma, and IL-10 in the active infection group were significantly lower than those in the VS group after suppression of the virus. The median slope of IFN-gamma production by means of PHA-stimulated culture after achieving VS status (4.04) was significantly higher than the level before VS status (-1.31, P =.004). The difference in the median slopes for IL-10 production by anti-CD3-stimulated cultures before (0.21) and after (-0.16) achieving VS status was statistically different (P =.027).
CONCLUSION: The immune restoration of HIV-1-infected children receiving HAART might be related to an increase in IFN-gamma production and a decrease in the rate of IL-10 production after virus suppression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170266     DOI: 10.1067/mai.2002.125979

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection.

Authors:  Samuel B Foster; Ming Lu; Daniel G Glaze; James M Reuben; Lynnette L Harris; Evan N Cohen; Bang-Ning Lee; Enxu Zhao; Mary E Paul; Heidi Schwarzwald; Chivon McMullen-Jackson; Charla Clark; F Daniel Armstrong; Pim Y Brouwers; Tracie L Miller; Andrew A Colin; Gwendolyn B Scott; Shahriar Shahzeidi; Elizabeth J Willen; Deshratn Asthana; Steven E Lipshultz; Bruce W Thompson; William T Shearer
Journal:  Clin Immunol       Date:  2012-05-02       Impact factor: 3.969

2.  Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

Authors:  Brian M Jones; Susan Ss Chiu; Wilfred Hs Wong; Wilina Wl Lim; Yu-Lung Lau
Journal:  J Int AIDS Soc       Date:  2005-05-03       Impact factor: 5.396

3.  Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

Authors:  Brian M Jones; Susan S S Chiu; Wilfred H S Wong; Wilina W L Lim; Yu-lung Lau
Journal:  MedGenMed       Date:  2005-05-03

4.  Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells.

Authors:  Evan N Cohen; Hui Gao; Simone Anfossi; Michal Mego; Neelima G Reddy; Bisrat Debeb; Antonio Giordano; Sanda Tin; Qiong Wu; Raul J Garza; Massimo Cristofanilli; Sendurai A Mani; Denise A Croix; Naoto T Ueno; Wendy A Woodward; Raja Luthra; Savitri Krishnamurthy; James M Reuben
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

5.  The effects of highly active antiretroviral therapy on the serum levels of pro-inflammatory and anti-inflammatory cytokines in HIV infected subjects.

Authors:  Faustina Nkechi Osuji; Charles Chinedu Onyenekwe; Joseph Ebere Ahaneku; Nkiruka Rose Ukibe
Journal:  J Biomed Sci       Date:  2018-12-03       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.